The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of n...ucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir, and entecavir in children aged 2–11 years) for first- and second-line treatment. Recommendations for the treatment of HBV/HIV-coinfected persons are based on the WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, which will be updated in 2015.
more
[Updated 2015]
SCOPING QUESTION: What is the effectiveness of psychosocial interventions (including caregiver skills training) for behavioural disorders in children and adolescents?
WHO would like to express its gratitude and appreciation to all Member States that provided information to the WHO survey on policies and activities at the national level in the area of antimicrobial resistance. The contribution of staff in WHO Regional and Country Offices has been invaluable: in ga...ther-ing original data and information from Member States, in supporting the process of aggregation of these data; and in reviewing the regional analysis of the findings that reflect the country situation at the point when the survey was conducted. The support and commitment of the members of the WHO Task Force on Antimicrobial Resistance, comprising WHO staff from Headquarters and Regional Offices has, is also acknowledged.
more
Le présent document a été élaboré pour aiderles comités de coordination RAM et d’autres comités chargés de la RAM au niveau des pays àparvenir à cet objectif. S’appuyant sur la littérature publiée ainsi que sur l’expérience opérationnelle et l’expertise de différents PRFI, le ...document présente six stratégies clés pour atteindre l’objectif et offre une série de conseils pratiques et de suggestions sur la façon de mettre en œuvre chacune d’entre elles.
more
The report will describe how the Ebola Response MPTF, which has attracted contributions from 38 Member States, one business and many individuals, has offered a transparent and strategic tool to support the Ebola response. As of 31 January 2015, the Fund had total pledges amounting to US$142 million,... out of which US$132 million have been deposited
more
Guidelines
HIV testing services
July 2015
Pre-exposure prophylaxis (PrEP)
Policy Brief
November 2015
The World Health Organization is issuing a "roadmap" to guide and coordinate the international response to the outbreak of Ebola virus disease in West Africa.
The aim is to stop ongoing Ebola transmission worldwide within 6–9 months, while rapidly managing the consequences of any further interna...tional spread. It also recognizes the need to address, in parallel, the outbreak’s broader socioeconomic impact.
more
With this World Health Day, WHO is drawing attention to a group of diseases that are spread by insects and other vectors, the heavy health and economic burdens they impose, and what needs to be done to reduce these burdens. Many of these diseases have been historically confined to distinct geographi...cal areas, but this situation has become more fluid due to a host of ills, including climate change, intensive farming, dams, irrigation, deforestation, population movements, rapid unplanned urbanization, and phenomenal increases in international travel and trade. The control of vector-borne diseases can make a major contribution to poverty reduction, as it precisely targets the poor
more
The report focuses on antibacterial resistance (ABR) in common bacterial pathogens. There is a major gap in knowledge about the magnitude of this problem. Antimicrobial resistance (AMR) threatens the effective revention and treatment of an ever-increasing range of infections caused by bacteria, para...sites, viruses and fungi. This WHO report, produced in collaboration with Member States and other partners, provides for the first time, as accurate a picture as is presently possible of the magnitude of AMR and the current state of surveillance globally. It examines the information on AMR, in particular antibacterial resistance (ABR), at country level worldwide.
more
Malaria is a prevalent cause of febrile illnesses in areas with high transmission, and its clinical presentation overlaps with initial signs of Ebola disease. For this reason, the effectiveness of the Ebola response in Guinea, Liberia and Sierra Leone can be optimized through the deployment of targe...ted measures to reduce the number of fever cases due to malaria
WHO recommends specific adaptations in the diagnosis of malaria and in LLIN distribution in countries heavily affected by the Ebola outbreak and mass drug administration using artemisinin-based combination therapies (ACTs) in areas where transmission of both Ebola and malaria is high and access to malaria treatment is very low.
more
(Mise à jour décembre 2014)